SwitzerlandSwitzerland

Merck Serono cheers Ablynx up with nanobodies pact

11.11.2011

Ghent/Geneva - Ablynx rides the biotech rollercoaster. Only days after US-pharma company Pfizer pulled out of a rheumatoid arthritis pact, the Belgian bipharmaceutical outfit expanded its relationship with Merck Serono. Ablynx entered into a third agreement to discover and develop Nanobodies together with the Swiss against two targets in osteoarthritis. Under the terms of the deal, Ablynx will receive an upfront payment of €20 million payable in two tranches over the next three months."Merck Serono is one of our most valued partners and the innovative and creative deal structure that we have put in place represents a win-win for both parties", said, Ablynx' CEO Edwin Moses. With this money, Merck buys an all inclusive package. Ablynx will be fully responsible for all activities and costs for each programme, excluding manufacturing, up to the delivery of the pre-clinical package that will form the basis of an Investigational New Drug filing or equivalent. If Merck likes what it sees, Ablynx will get a further 15 million euros for each programme. At that point, Ablynx has the option to continue with Merck Serono on a 50:50 co-development basis and share the resulting profits, or to convert this collaboration into an exclusive, worldwide licensing deal with milestone payments and tiered royalties. The companies have been partners since 2008. In September 2008, Merck Serono and Ablynx entered into an agreement to co-discover and co-develop Nanobodies against two disease targets in oncology and immunology. In October 2010, the companies entered into a second agreement to co- discover and co-develop Nanobodies against an inflammatory disease target.


SwitzerlandSwitzerland

30.03.2012

Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...

SwitzerlandSwitzerland

27.03.2012

London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...

SwitzerlandSwitzerland

26.03.2012

Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...

SwitzerlandSwitzerland

09.03.2012

After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...

SwitzerlandSwitzerland

08.03.2012

The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...

SwitzerlandSwitzerland

06.03.2012

Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...

SwitzerlandSwitzerland

06.03.2012

Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....

SwitzerlandSwitzerland

05.03.2012

Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-switzerland/article/merck-serono-cheers-ablynx-up-with-nanobodies-pact.html

Stock list

All quotes

TOP

  • WILEX (D)3.11 EUR288.75%
  • NOVACYT (F)5.00 EUR18.76%
  • OREXO (S)137.25 SEK11.13%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.11 EUR326.0%
  • SANTHERA (CH)67.60 CHF109.0%
  • ADDEX (CH)4.19 CHF91.3%

FLOP

  • MERCK KGAA (D)64.02 EUR-50.5%
  • VERONA PHARMA (UK)1.07 GBP-48.6%
  • THROMBOGENICS (B)8.38 EUR-48.3%

TOP

  • SANTHERA (CH)67.60 CHF3314.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • PHARMING (NL)0.51 EUR325.0%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.38 EUR-73.0%

No liability assumed, Date: 21.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events